Will Your Prescription
Cost More in 2026?
The US government is imposing up to a 100% tariff on brand-name drugs. Search your medication for instant tariff status.
Powered by OpenFDA + CMS NADAC government data · No account required
Tariff Tiers
6 Rates. One Proclamation.
Default tariff
No deal, no exemption
Onshoring plan
Committed to US production
EU / Japan / Korea
Country-specific rate
UK manufacturer
UK bilateral rate
MFN deal (13 cos.)
Annex III company agreement
Generic / exempt
Fully exempt — no tariff ever
100%
Default tariff
Brand-name patented drugs
13
MFN deal companies
Pay 0% under Annex III
0%
Tariff on generics
Fully exempt, always
FAQ
Common Questions
What Is the Section 232 Pharmaceutical Tariff?
On April 2, 2026, the Trump administration invoked Section 232 of the Trade Expansion Act of 1962 to impose tariffs on pharmaceutical imports. The default rate is 100% on all patented brand-name prescription drugs manufactured outside the United States without an approved exemption — the same authority previously used for steel and aluminum tariffs.
The tariff is structured into six tiers. Companies that signed MFN deals — including AbbVie, Eli Lilly, Merck, Novo Nordisk, Sanofi, and eight others — pay 0% with an earlier effective date of July 31, 2026.
Critically, generic drugs and biosimilars are entirely exempt. Since approximately 90% of all US prescriptions are filled with generics, the majority of patients are insulated from the tariff's direct effects. Use this tool to check your specific medication using real government data from OpenFDA and the CMS NADAC database.